Alk-Abello AS logo

Alk-Abello AS

AKBLF · OTC · Pharmaceuticals, Biotech · Founded 1923

ALK-Abello A/S engages in the production and development of pharmaceutical products to prevent and treat allergies. The firm manufactures tablet-based allergy vaccines for pollen, house dust mites, animals, and insect stings. Its treatment comprises allergy vaccines, emergency treatment, and allergy diagnostics.

Current Price
—
Market Cap
—
Return Since Last Split
+112%
Last Split
Mar 28, 2022
Total Splits
1
Cumulative Multiple
20×

What If You Bought AKBLF Earlier?

Investment
Purchase Date (Before Split)
Worth Today
—
2,000 shares · 20×

Estimate based on split history only. Excludes dividends, fees, taxes, and intraday movement.

Stock Split History

Newest split first. Cumulative multiple = compounded growth within the displayed company lineage.

Split DatePrice BeforeRatioSplit MultipleCumulative
Mar 28, 2022$18.1320-for-120×20×

Alk-Abello AS Market Cap Timeline

A validated annual market-cap history is unavailable from the current sources. The current market-cap snapshot, when shown above, is not treated as historical evidence. Split markers cover 1 current-security split. Filled dots have market-cap data for that year; hollow dots mark split years outside market-cap source coverage.

Validated annual history unavailable

At least two source-validated annual observations are required before this page draws a market-cap timeline. A current snapshot is not treated as historical trend data.

Recorded split dates

Frequently Asked Questions

Alk-Abello AS's latest record in the split calendar is a 20-for-1 forward split effective 2022-03-28.
Stay in the loop

Never Miss a Stock Split Again

Get personalized stock split alerts. Choose what you receive and how often.

Your email is securely stored. We’ll only contact you about updates you choose. Unsubscribe anytime.